Biotechnology

Vibrant Wellness Tickborne Testing Granted New York State Approval

March 29, 2024 9:15 AM

A Significant Milestone in Lyme and Tickborne Diagnostics SANTA CLARA, CA / ACCESSWIRE / March 29, 2024 / Vibrant Wellness, a leader in specialized diagnostics and personalized health tools, announced today that its Tickborne Testing received approval from The Wadsworth Center, part of the New York State Department of Health. This approval enables Vibrant to provide Lyme disease testing in New York, specifically for Borrelia Burgdorferi IgG/IgM...

Read more

Cambridge-Based Biotech SynDevRx Announces Scientific Publication Describing Optimized Drug Conjugate Targeting Tumors Sensitive to Obesity/Metabolic Hormones

March 28, 2024 10:00 AM

Innovative pro-drug delivers superior efficacy with improved drug-like properties and safety profile CAMBRIDGE, MA / ACCESSWIRE / March 28, 2024 / SynDevRx, Inc., a pioneering clinical-stage biotechnology company based in Cambridge, Massachusetts, has achieved a significant milestone. The company is delighted to announce the publication of a peer-reviewed research paper describing its optimized MetAP2 inhibitor, evexomostat/SDX-7320, targeting...

Read more

Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

March 28, 2024 8:15 AM

Topline Results For Progression-Free Survival Expected In Q2 2024 CARDIFF, UK / ACCESSWIRE / March 28, 2024 / Biodexa Pharmaceuticals (NASDAQ:BDRX) ("Biodexa"), an acquisition-focused biopharmaceutical company, is developing MTX110 for the treatment of Diffuse Midline Glioma (DMG) in pediatric patients and for Recurrent Glioblastoma (rGBM) in adults; two aggressive brain cancers with universally poor prognoses. The company says early trials of...

Read more

Globestar Therapeutics Update on Project Amethyst(TM) and Recent Financials

March 28, 2024 8:15 AM

RICHLAND, WA / ACCESSWIRE / March 28, 2024 / GlobeStar Therapeutics Corporation (OTC PINK:GSTC) (GSTC), is a clinical stage pharmaceutical company focused on advancing new therapies for Multiple Sclerosis (MS) and other neurological diseases, including but not limited to Rheumatoid Arthritis (RA), released on March 11, 2024 its fiscal year first quarter financials for the quarter ended 12/31/2023. The Company reported that $42,800 of cash was...

Read more

Revolutionizing EV Research: Introducing ONI's Next-Generation End-to-End Solution

March 28, 2024 7:00 AM

SAN DIEGO, CA / ACCESSWIRE / March 29, 2024 / ONI, the company that brought super-resolution microscopes to your lab benchtop, proudly announces the launch of a next-generation, end-to-end solution for studying extracellular vesicles (EVs). ONI now offers a complete solution for extracellular vesicle sample preparation and analysis, the ONI Application Kit™: EV Profiler 2 with the analysis software AutoEV. Together, they are designed to instill...

Read more

Vicore Announces Presentations at the 2024 American Thoracic Society International Conference

March 28, 2024 3:30 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / March 28, 2024 / Vicore Pharma Holding (STO:VICO) Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPF Additional presentations include preclinical and translational data reflecting the potency of buloxibutid's upstream mechanism of action as well as the design of the upcoming Phase 2b ASPIRE trial Vicore also to be featured in...

Read more

Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights

March 28, 2024 3:00 AM

LONDON, UK / ACCESSWIRE / March 28, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 28 March 2024 consists of 1,341,815,988 ordinary shares of 1 pence each, none of which are held in treasury. Therefore, the total number of voting rights in the...

Read more

Notice to Annual General Meeting in BioInvent International AB

March 27, 2024 10:15 AM

LUND, SWEDEN / ACCESSWIRE / March 27, 2024 / BioInvent International (STO:BINV) The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m., 3 May 2024 at Elite Hotel Ideon on Scheelevägen 27 in Lund, Sweden. The Board of Directors has decided that shareholders shall be able to exercise their voting rights at the Annual General Meeting also by voting...

Read more

Vicore Publishes the Annual Report for 2023

March 27, 2024 3:20 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / March 27, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, March 27, 2024 - Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced the publication of the Annual Report for the financial year 2023. The Annual Report for the financial year 2023 is available on the company's website:...

Read more

Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals

March 26, 2024 4:30 PM

WOBURN, MA / ACCESSWIRE / March 26, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that its 2024 Annual Meeting of Stockholders will be held on June 12, 2024 and that the close of business on April 22, 2024 will be the record date for the determination of stockholders entitled to notice of and to vote at the 2024 Annual Meeting....

Read more

InnoSIGN Appoints Eric Lindquist Chief Executive Officer

March 26, 2024 9:00 AM

MASON, OH and EINDHOVEN, THE NETHERLANDS / ACCESSWIRE / March 26, 2024 / InnoSIGN a clinical stage biotechnology company focused on democratizing precision medicine through its proprietary cell signaling pathway technology, today announced the appointment of Eric Lindquist as Chief Executive Officer (CEO). Eric will succeed Paul van de Wiel, PhD, co-founder and previous CEO, who will remain as Chief Operating Officer and Board observer. "We are...

Read more

assisTek Unveils Cutting-Edge Technology Platform to Elevate Clinical Trial Data Collection

March 26, 2024 9:00 AM

Transforming Clinical Research: assisTek's Innovative New Platform Raises the Bar for Data Collection and Patient Impact DOYLESTOWN, PA / ACCESSWIRE / March 26, 2024 / assisTek, a leading innovator in e-clinical solutions for clinical research, proudly unveils its latest breakthrough: an innovative eCOA platform designed to provide a state-of-the-art user experience in order to enhance the ease of clinical trial data collection. Through the...

Read more

A Revolutionary Breakthrough in Biomedical Testing: AmeboGenesis Introduces Sustainable Amebocyte Production for LAL Testing to Detect Bacterial Contamination

March 26, 2024 7:15 AM

Limulus Amebocyte Lysate (LAL) Can Now Be Produced Without Harvesting the Blood of ~800,000 Horseshoe Crabs Each Year, Which Will Help Restore Their Natural Population GERMANTOWN, MD / ACCESSWIRE / March 26, 2024 / AmeboGenesis™ has achieved a significant milestone with the introduction of a sustainable Amebocyte production process. This innovative technology produces bio-identical Amebocytes necessary for the production of LAL for medical...

Read more

Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call

March 25, 2024 5:00 PM

Call Scheduled for Monday, April 1st, 2024, at 4:30 pm ET NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Company plans to hold its first investor earnings call to discuss the results contained in its FY 2023 Form 10K, which it plans to file that day, and its outlook for FY 2024. The Company plans to hold its earnings call, open to the public, at 4:30 pm...

Read more

Faro Health Inc. Appoints Patrick Leung as Chief Technology Officer

March 25, 2024 9:00 AM

SAN DIEGO, CA / ACCESSWIRE / March 25, 2024 / Faro Health Inc., the emerging leader in clinical trial development using AI to optimize protocol design and outcomes, is pleased to announce the appointment of Patrick Leung as Chief Technology Officer. This appointment comes at a time of significant momentum for Faro Health as it continues to evolve its AI-based platform for optimal clinical trial design and document generation. Patrick is a native...

Read more

MRES: M2Bio Food and Beverage Wraps Up 2023/ 2024 Looking Ahead

March 22, 2024 10:15 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / March 22, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specialising in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to announce the following updates with its M2Bio Food and Beverage division: M2Bio Sciences...

Read more

Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results

March 22, 2024 8:00 AM

Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with $9.0 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / March 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies...

Read more

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

March 21, 2024 4:30 PM

TORONTO, ON / ACCESSWIRE / March 21, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate in a Fireside Chat and host one-on-one meetings at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 28, 2024. The Fireside Chat discussion between Edesa's Chief...

Read more

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

March 21, 2024 4:05 PM

- Initiated enrollment of DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial in Q4 2023 - - Raised $9.1 million in gross proceeds from three financings completed in 2023 - - Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis - SAN DIEGO, CA / ACCESSWIRE / March 21, 2024 ./ Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology...

Read more

Public Health Vaccines Announces Initiation of First Clinical Trial Evaluating Its Marburg Virus Vaccine

March 21, 2024 8:00 AM

CAMBRIDGE, MA / ACCESSWIRE / March 21, 2024 / Public Health Vaccines, LLC (PHV), a biotechnology company out of Cambridge, Massachusetts, developing novel products against emerging infectious diseases, has started its Phase 1 clinical trial (NCT06265012) to evaluate the safety and immunogenicity of the company's single-dose vaccine (PHV01) against Marburg virus - a hemorrhagic fever virus of the Filoviridae family that causes Marburg virus...

Read more